Oncolytics Biotech (ONCY) Cash from Investing Activities (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Cash from Investing Activities data on file, last reported at -$6226.0 in Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 44.96% year-over-year to -$6226.0 in Q4 2025; TTM through Dec 2025 was -$147305.6, a 15.93% increase from a year earlier, with the FY2025 full-year figure at -$6000.0, up 96.55% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at -$6226.0, down from -$4295.1 in the prior quarter.
• Over the last five years, Cash from Investing Activities for ONCY reached as high as $5.1 million in Q2 2023 and fell as low as -$15.0 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$25638.2 across 5 years, with a median of -$8017.2 in 2022.
• Across the five-year window, Cash from Investing Activities sank 25452.66% in 2021 and soared 73236.84% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$59313.0 in 2021, then sank by 25172.2% to -$15.0 million in 2022, then jumped by 99.99% to -$2203.6 in 2023, then tumbled by 94.91% to -$4295.1 in 2024, then sank by 44.96% to -$6226.0 in 2025.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$6226.0 in Q4 2025, -$4295.1 in Q4 2024, and -$23457.7 in Q3 2024.